Kodiak Sciences (KOD) Why AMD fueled the stock 180% Higher
Kodiak Sciences stock surged over 170% following encouraging Phase 3 trial data for wet age-related macular degeneration treatments Zenkuda and KSI-501, which…
Kodiak Sciences stock surged over 170% following encouraging Phase 3 trial data for wet age-related macular degeneration treatments Zenkuda and KSI-501, which…
AMD shares declined 3.61% following a record-breaking peak that pushed its market cap past $1 trillion. The pullback reflects profit-taking, climbing oil…